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Background: Sorafenib (Nexavar©R ) is an FDA-approved systemic therapy for advanced
hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high
doses limit the clinical application of sorafenib and strongly recommend its combination
with other agents aiming at ameliorating its drawbacks. OSU-2S, a PKCδ activator, was
selected as a potential candidate anticancer agent to be combined with sorafenib to
promote the anti-cancer activity through synergistic interaction.
Methods: The antitumor effects of sorafenib, OSU-2S and their combination were
assessed by MTT assay, caspase activation, Western blotting, migration/invasion
assays in four different HCC cell lines. The synergistic interactions were determined by
Calcusyn analysis. PKCδ knockdown was used to elucidate the role of PKCδ activation
as a mechanism for the synergy. The knockdown/over-expression of p53 was used to
explain the differential sensitivity of HCC cell lines to sorafenib and/or OSU-2S.
Results: OSU-2S synergistically enhanced the anti-proliferative effects of sorafenib in
the four used HCC cell lines with combination indices <1. This effect was accompanied
by parallel increases in caspase 3/7 activity, PARP cleavage, PKCδ activation and
inhibition of HCC cell migration/invasion. In addition, PKCδ knockdown abolished the
synergy between sorafenib and OSU-2S. Furthermore, p53 restoration in Hep3B cells
through the over-expression rendered them more sensitive to both agents while p53
knockdown from HepG2 cells increased their resistance to both agents.
Conclusion: OSU-2S augments the anti-proliferative effect of sorafenib in HCC cell
lines, in part, through the activation of PKCδ. The p53 status in HCC cells predicts their
sensitivity toward both sorafenib and OSU-2S. The proposed combination represents a
therapeutically relevant approach that can lead to a new HCC therapeutic protocol.
Keywords: OSU-2S, sorafenib, hepatocellular carcinoma, cancer resistance, PKCδ, p53
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common type of liver tumors and a leading cause
of cancer-associated death worldwide. HCC usually develops as a primary malignancy in patients
suffering from chronic liver diseases and liver cirrhosis (Omar et al., 2011). A major challenge in
the non-operative management of HCC is the cellular resistance to conventional anticancer agents,
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which may be attributed to the heterogeneity of genetic
abnormalities acquired during the course of carcinogenesis
(Pancione et al., 2012).
Sorafenib is an orally bioavailable multikinase inhibitor, which
is approved for the treatment of unresectable advanced HCC
(Wilhelm et al., 2006; Llovet et al., 2008). It works mainly
through the inhibition of cancer cell survival pathways, such
as RAF kinases, vascular endothelial growth factor and platelet-
derived growth factor (Strumberg, 2005). Among many other
targeted therapies for HCC, which are under development,
sorafenib is currently the only FDA-approved systemic therapy
for advanced HCC (Worns and Galle, 2010). However, in
clinical practice, sorafenib exhibited low efficacy with a limited
improvement in the median survival of HCC patients, which
could be due to de novo resistance or the dose reductions
to avoid the full dose adverse effects (Al-Rajabi et al., 2015;
Federico et al., 2015). Therefore, combination therapies with
sorafenib aiming at increasing the anticancer efficacy and
reducing the required doses and consequently, minimizing
the adverse effects and prolonging the patient survival are
strongly encouraged (Hikita et al., 2010; Xie et al., 2012; Hu
et al., 2016). In addition, the need for combination therapy
is supported by the fact that targeting cell survival pathways
in cancer cells by monotherapy is usually unsuccessful due
to the ability of cancer cells to compensate for the affected
targets by activating alternative compensatory pathway, a
phenomenon known as redundancy (Li et al., 2014; Lavi,
2015).
One of the successful approaches in combination therapy is to
select novel agents targeting different signaling pathways without
significant systemic toxicity (Morisaki et al., 2013). Accordingly,
OSU-2S was selected as a potential candidate anticancer agent to
be combined with sorafenib to promote the anti-cancer activity
and lower their therapeutic doses through the possible synergistic
efficacy. OSU-2S is a novel anti-cancer agent that was designed
and developed to selectively avert the immunosuppressive effects
and related toxicities of its predecessor analog, FTY720 (Adachi
and Chiba, 2008; Omar et al., 2011; Mao et al., 2014).
Previous in vitro studies showed the promising cytotoxicity of
OSU-2S in many cancer cells, such as chronic lymphocytic
leukemia (CLL), mantle cell lymphoma (MCL), acute
lymphoblastic leukemia (ALL) (Bai et al., 2011). OSU-2S
also demonstrated high efficiency in suppressing HCC in vivo
without causing any immunosuppressive effect (Omar et al.,
2011). The anti-proliferative mechanism of OSU-2S in HCC
is mediated through the activation of reactive oxygen species-
PKCδ signaling pathways and the subsequent induction of
caspase-dependent apoptosis (Omar et al., 2011).
In the current study, we aimed to test the potential synergy
between OSU-2S and sorafenib as a new therapeutic modality
for the treatment of HCC which can exploit the maximal
benefit through mechanistic synergy. We hypothesize that OSU-
2S-induced modulation of PKCδ/p53 signaling plays a key
role in augmenting sorafenib antitumor activity in HCC cells.
The suggested combination therapy should increase sorafenib
therapeutic gain and address the recently expressed safety
concerns.
MATERIALS AND METHODS
Material
OSU-2S (Figure 1A) was synthesized in Dr. Chen’s lab at The
Ohio State University as previously described (Omar et al.,
2011). The identity and purity of OSU-2S were verified by
mass spectrometry analysis and HPLC, respectively. Sorafenib
(BAY 43-9006) (Figure 1A) was purchased from BioVision R©
(Milpitas, CA, USA). OSU-2S and sorafenib were dissolved
in DMSO and diluted in culture medium. Fetal bovine
serum and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide] were purchased from (Sigma-Aldrich, St.
Louis, MO, USA). The enhanced chemiluminescence system,
Matrigel and 24-well modified Boyden chambers (8 µm
pore size) were obtained from GE Healthcare Bioscience
(Piscataway, NJ, USA), BD Biosciences (Bedford, MA, USA)
and Corning Costar (Cambridge, MA, USA), respectively.
Antibodies against various biomarkers were obtained from the
following sources: PKCδ, ERKs, pERKs, from cell Signaling
Technologies (Beverly, MA, USA); Poly(ADP-ribose) polymerase
from Pharmingen (San Diego, CA, USA); β-actin from Sigma-
Aldrich (St. Louis, MO, USA); Caspase 3 and p53 from
Novus Biologicals (Littleton, CO, USA). Mammalian PKCδ
shRNA expression plasmid (pKD-PKCδ-v2) and random shRNA
(pKD-NegCon-v1) were purchased from Upstate (Temecula,
CA, USA). Mammalian p53 shRNA expression plasmid, shp53
pLKO.1 puro was a gift from Bob Weinberg (Addgene plasmid
# 19119), pLKO.1 – TRC control non-silencing plasmid was
a gift from David Root (Addgene plasmid # 10879), GFP-p53
was a gift from Tyler Jacks (Addgene plasmid # 12091) and
the empty vector, pEGFP-N1-FLAG was a gift from Patrick
Calsou (Addgene plasmid # 60360). Other chemicals and
reagents were obtained from Sigma-Aldrich unless otherwise
mentioned.
Cell Culture
The HCC cells were cultured in Dulbecco’s Modified Eagle’s
medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 10% fetal bovine serum, 1.5 g/L sodium
bicarbonate and 1% penicillin/streptomycin. PLC5 and HepG2
cells were obtained from the American Type Culture Collection
(Manassas, VA, USA) while Hep3B and Huh7 cells were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Cell lines
were maintained at 37◦C in a humidified incubator containing
5% CO2.
Cell Viability and Synergy Analyses
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay was used for cell viability analysis as described
before (Hung et al., 2015). In summary, HCC cells were seeded
in 10% FBS supplemented DMEM at 1 × 104 cells per well
density in 96-well flat-bottomed plates. The cells were treated
with different concentrations of OSU-2S, sorafenib or their
combination after 24 h of cell seeding. An equivalent volume
of the used vehicle (DMSO) was used for the control treatment.
After 48 h of treatment, the media were removed by aspiration
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FIGURE 1 | Anti-proliferative effects of sorafenib and OSU-2S in HCC cell lines. (A) Chemical structures of OSU-2S and sorafenib. HCC cells were treated
with sorafenib (B) or OSU-2S (C) at the indicated concentrations in 10% FBS-supplemented Dulbecco’s modified Eagle’s medium (DMEM) in 96-well plates for 48 h,
and cell viability was assessed by MTT assays. Points, mean; bars, SD (n = 6). (D) The IC50 values of sorafenib and OSU-2S in four HCC cell lines calculated from
MTT assays. All data are depicted as mean ± SD (n = 6).
and replaced by 200 µL fresh media containing 0.5 mg/mL
of MTT then incubated in the CO2 incubator at 37◦C for
2 h. At the end of the experiment, the supernatants were
removed and the formed formazn crystals were dissolved in
200 µL/well DMSO. The intensity of the formed violet color
was measured at 570 nm using a plate reader. Following plate
reading, the data were analyzed by CalcuSyn software package
version 2.1 (Biosoft, Cambridge, UK), which is based on the
median effect equation to calculate the combination index
(CI) of different treatments. The cell viability was expressed
as percent cell vialbilty relative to the vehicle-treated control
group.
Western Blot
Lysates of OSU-2S-treated HCC cells at the indicated
concentrations for 48 h were prepared for Western blotting
of PARP, PKCδ, ERK1/2, pERK1/2, caspase 3, p53, and β-actin.
Western blot analysis was performed as formerly reported (Arafa
el et al., 2014).
Caspase 3/7 Activity Assay
Caspase-3/7 activities in HCC cells treated with OSU-2S,
sorafenib, or their combination were measured using Caspase-
Glo 3/7 luminescence assay kit according to the manufacturer’s
directions (Promega, Madison, WI, USA). The vehicle (DMSO)
was used as negative control. In a brief, cells were seeded at
1 × 104 (100 µl/well) into clear bottom, opaque wall 96-well
tissue culture plates and incubated for 24 h. Cells were treated for
24 h and caspase-3/7 activities were assayed a plate luminometer.
Invasion Assays
The assay with performed essentially as detailed before (Omar
et al., 2013) with minor modifications. Hep3B cells were
trypsinized and suspended in 0.5 ml of serum-free medium
containing different concentrations of OSU-2S, sorafenib or
their combination. The cell suspensions were seeded onto the
membranes of the upper chambers of modified Boyden chambers
(8 µm; Corning Costar, Cambridge, MA, USA) which were
pre-coated with Matrigel. The lower chambers contained the
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same concentrations of the used agents in 10% FBS-containing
medium. The cells were then incubated at 37◦C for 24 h. After
incubation, the cells remaining on the upper surface of the
membranes were removed gently with cotton swabs. Cells which
invaded into the lower surface of the membrane were fixed in 90%
methanol and stained with 0.1% crystal violet. Stained cells were
counted in at least ten 200x fields.
Migration Assays
For the measurement of the ability of test compounds to affect
cancer cell migration, the Modified Boyden chambers were used
as mentioned before (Omar et al., 2009). Briefly, Hep3B in 0.5 ml
of serum-free DMEM containing different concentrations of the
used agents were seeded into the upper chamber membranes.
The cells were incubated at 37◦C for 60 min, then transferred to
new wells containing the same concentrations of the used agents
in 10% FBS-supplemented DMEM, and then incubated for 8 h.
Non-migrated cells on the upper surface of each membrane were
swabbed gently, while migrated cells into the lower side of the
membrane were fixed, stained and counted as mentioned above.
Short Hairpin (sh) RNA-Mediated PKCδ
or p53 Knockdown
Hepatocellular carcinoma cells were transfected with shRNA
plasmids for the knockdown of PKCδ, p53 or control vector
using Lipofectamine 2000 (Life Technologies) according to the
manufacturer protocol. Transfected cells with pKD-PKCδ-v2
were further subjected to stable clone isolation by 500 µg/ml
geneticin (Invitrogen, Carlsbad, CA, USA) and antibiotic-
resistant colonies were isolated after 2–3 weeks. The knockdown
of the corresponding protein was confirmed by immunoblotting.
Overexpression of p53
Hep3B cells were transfected with 1 µg/ml of plasmids DNA
encoding GFP-p53 or the empty vector, pEGFP-N1-FLAG using
Lipofectamine 2000 according to the manufacturer’s instructions
and as mentioned before (Cai and Liu, 2008). The expression of
p53 was confirmed by both Western blotting and fluorescence
microscopy.
Statistical Analysis
The analysis of statistical significance between different
treatments was performed using one-way ANOVA followed by
the Neuman–Keuls test for multiple comparisons. Differences
were considered significant at P < 0.05. Statistical analysis was
performed using SPSS for Windows (SPSS, Inc., Chicago, IL,
USA).
RESULTS
OSU-2S Sensitizes HCC Cells to
Sorafenib-Mediated Anti-proliferative
Effect
The ability of OSU-2S and sorafenib as a single agent to
inhibit the cell viability of HCC cell lines has been reported
before (Ng and Chen, 2006; Omar et al., 2011). In order to select
a suitable range of drug concentrations for combination
experiments, the effect of both sorafenib and OSU-2S on the cell
viability of four different HCC cell lines was initially investigated
using MTT assay. The dose response curve of sorafenib or
OSU-2S was assessed relative to vehicle control treatment
(Figures 1B,C). The half maximum inhibitory concentration
(IC50) for OSU-2S was in the range of 1.8–3.9 µM with the
HepG2 cells being the most sensitive and the PLC-5 cells being
the most resistant. For sorafenib, the IC50 was in the range of 6.2–
10.4 µM with HepG2 cells being the most sensitive and Hep3B
cells being the most resistant (Figure 1D). Sorafenib-mediated
anti-proliferative effect was significantly enhanced upon the
combination with OSU-2S. Combination indexes (CI) were
calculated using Calcusyn software for each dose combination.
Values of CI <1 indicate synergy, =1 indicate additive effect and
>1 indicate antagonism. Synergistic effects were observed in the
four used HCC cell lines with different degrees. For example,
in HepG2, Hep3B, and PLC-5 cells, almost all the selected dose
levels showed synergistic effect. While in Huh7 cells, 2 out of
4 of the combination concentrations showed additive effects
(Figure 2).
OSU-2S Sensitizes HCC Cells to
Sorafenib-Mediated Anti-proliferative
Effect
The ability of sorafenib/OSU-2S combination to elicit apoptotic
cell death compared to single drug treatment was initially tested
using caspases 3/7 activity assay. For this experiment, Hep3B
cells were selected since it was the most resistant to sorafenib
as a single agent. Results showed that increasing doses of
OSU-2S dramatically increased sorafenib-induced activation of
caspases 3/7 (1.5- to 3-fold increase) especially at 2.5 µM dose
level of OSU-2S (Figure 3A). These results were confirmed
by Western blotting of two hallmarks of apoptosis, caspase 3
and its downstream target protein, PARP. The results showed a
significant increase in caspase 3 activation through cleavage with
a parallel increase in PARP cleavage (Figure 3B).
In addition, the possible modulatory effects of OSU-2S on the
reported anticancer mechanism of sorafenib were investigated
by Western blotting of ERK1/2 phosphorylation, which is
considered as a major target of sorafenib (Adnane et al., 2006;
Manov et al., 2011). Results showed that OSU-2S increased
the inhibitory effect of sorafenib on ERK1/2 phosphorylation
(Figure 3B). At the same time, sorafenib/OSU-2S combination
displayed a significant increase in PKCδ activation as a reported
mechanism for OSU-2S and another biomarker for apoptosis
(Omar et al., 2011) (Figure 3B).
Sorafenib/OSU-2S Combination Inhibits
In vitro Cell Migration/Invasion of HCCs
The ability of OSU-2S to synergize the effect of sorafenib on
endothelial cell migration/invasion was analyzed by modified
Boyden’s chamber assay. Only cancer cells with high migratory
ability can pass through the Boyden’s chamber membrane
of 8 µm pore. Sorafenib effectively inhibited the ability of
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FIGURE 2 | OSU-2S/sorafenib synergistic combination. (A) HepG2, Huh7, Hep3B, and PLC5 cell lines were treated with sorafenib or OSU-2S at the indicated
concentrations in 10% FBS-DMEM plates for 48 h, and cell viability was assessed by MTT assays. Columns, mean; bars, SD (n = 6). (B) OSU-2S/sorafenib
combination algebraic estimate calculated by Calcusyn software. (C) A table showing the fraction affected (Fa) and OSU-2S/sorafenib combination indices (CI) at the
indicated dose levels in four different HCC cell lines.
HCC cells to invade Matrigel-coated membranes in a dose-
dependent manner (Figure 3C). In addition, sorafenib inhibited
the migratory ability of HCC cells through the porous inserts
(Figure 3D). The sorafenib/OSU-2S combination showed a
significant synergy in sorafenib-mediated inhibition of both
migration and invasion.
Sorafenib/OSU-2S Combination Synergy
Is, in Part, Mediated through PKCδ
Activation
PKCδ, a pro-apoptotic kinase, is involved in caspase-3-dependent
apoptotic pathway in HCC (Reyland, 2007; Hung et al., 2008).
The role of PKCδ activation as a possible mechanism for the
synergy between sorafenib and OSU-2S was studied through the
knockdown of PKCδ of from Hep3B and Huh7 cell lines. The
knockdown of PKCδ protein was initially confirmed by Western
blotting and the stable clones with the lowest expression levels
of PKCδ was used for the following MTT analysis (Figure 4A).
PKCδ knockdown caused a significant increase in the resistance
of both Hep3B and Huh7 to sorafenib and OSU-2S with about 2-
to 3.5-fold increase in the IC50 (Figures 4B,C). In addition, PKCδ
knockdown completely eliminated the synergy between sorafenib
and OSU-2S in their combination as indicated by all CI values
over 1 (Figure 4D). These results suggested the activation of
PKCδ as a putative mechanism for synergistic sorafenib/OSU-2S
combination.
The Role of p53 in the Sensitivity of HCC
Cells to Both Sorafenib and OSU-2S
The used HCC cell lines showed differential sensitivity to
both sorafenib and OSU-2S. HepG2 was the most sensitive
to both drugs. Among the four used HCC cell lines in this
study, only HepG2 cells have wild type functional p53 while
the others lack functional p53 due to deletion or mutation
(Lee et al., 2002). Based on this observation and based on
the central role of p53 in apoptotic cell death, the lack
of functional p53 in Hep3B postulated as a mechanism of
resistance. To elucidate the possible role of the presence of
functional p53 in HCC cells in the sensitivity or the resistance
of sorafenib and OSU-2S, p53 knockdown was performed in
HepG2 cells followed by MTT assay. Results showed that the
p53 knockdown caused a significant increase in the resistance
of HepG2 cells toward both sorafenib and OSU-2S with IC50
values of 9.9 and 6.1 µM, respectively, which is almost doubling
of the IC50 values (Figures 5A–C). In addition, p53 over-
expression was performed in Hep3B cells, which were the
most resistant to sorafenib followed the MTT assay. The
results showed that restoring the activity of p53 caused the
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FIGURE 3 | OSU-2S sensitizes HCC Cells to sorafenib-mediated anti-proliferative effect. (A) Caspase 3/7 activities were measured using the Caspase-Glo
Assay Kit and (B) Western blot analysis of the expression levels of PARP, PKCδ, pERK1/2, ERK1/2 and caspase-3 in Hep3B cells after the indicated treatment for
48 h in 10% FBS-supplemented DMEM. All data are depicted as ±SD (n = 6). Effects of sorafenib/OSU-2S combination on Hep3B cells (C) invasion and (D)
migration. Columns, mean; bars, SD (n = 10).
Hep3B cells to be much more sensitive to both sorafenib and
OSU-2S with IC50 values of 3.2 and 1.9 µM, respectively
(Figures 6A–C). Furthermore, the anti-proliferative activity of
sorafenib/OSU-2S combination was significantly increased upon
p53 restoration by the overexpression as indicated by the
progressive morphological changes from flat to round in Hep3B-
p53-GFP which are characteristic of apoptosis (Figure 6D). These
results suggested a significant role of p53 in the sensitivity of
HCC cells to both sorafenib and OSU-2S as single agents or in
combination.
DISCUSSION
The low efficacy of sorafenib in clinical practice due to de novo
resistance or dose reductions to avoid the full dose adverse
effects raised the current need for combination therapies with
sorafenib (Hikita et al., 2010; Xie et al., 2012; Federico et al.,
2015). The present study provides an evidence on the synergistic
combination of sorafenib with the novel anticancer agent,
OSU-2S and sheds light on their mechanism of synergy and
translational potential into clinical application. In a previous
study, we have addressed the anti-proliferative mechanism of
OSU-2S in HCC, both in vitro and in vivo, through the activation
of PKCδ signaling pathways and the subsequent induction of
caspase-dependent apoptosis (Omar et al., 2011).
The design of sorafenib/OSU-2S combination was based on
the ability of sorafenib to induce p53 family-dependent apoptosis
in HCC and the lack of functional p53 in most HCC cells which
could be a possible mechanism for sorafenib resistance (Brost
et al., 2013; Wei et al., 2015). Then, it was rational to combine
sorafenib with OSU-2S to overcome sorafenib resistance through
the ability of OSU-2S to activate PKCδ signaling which, in turn,
stimulates p53-dependent and -independent apoptotic cell death
pathways (Hew et al., 2011).
As single agents, OSU-2S or sorafenib exhibited moderate
anticancer activities against the used HCC cell lines while
their combinations were potentially synergistic. The synergy
was supported by the observed increase in apoptotic cell
death hallmarks like caspase 3/7 activation and PARP cleavage.
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FIGURE 4 | PKCδ Knockdown abolishes the synergy between sorafenib and OSU-2S. The effect of PKCδ Knockdown on the anti-proliferative activity of
sorafenib/OSU-2S combination. (A) Western blot analysis of the differential expression levels of PKCδ in untransfected (left) Hep3B and (right) Huh7 cells versus
different corresponding stable clones. Effect of sorafenib/OSU-2S combination on (B) the viabilities of (left) Hep3B and (right) Huh7 cells stable clones with PKCδ
Knockdown (#1 and #3), (C) The combination algebraic-estimate and (D) the combination indices. Columns, mean; bars, SD (n = 6).
From a mechanistic perspective, OSU-2S displays a unique
ability to activate PKCδ and caspase-dependent apoptosis (Omar
et al., 2011). The hypothesis that OSU-2S augmented the anti-
proliferative effect of sorafenib in HCC cell lines, in part, through
the activation of PKCδ was supported by the absence of synergy
upon PKCδ knockdown.
PKCδ has a contrasting role in regulating apoptotic cell death,
either proapoptotic or antiapoptotic, in different cell systems
(Brodie and Blumberg, 2003; Basu and Pal, 2010). Previously,
Hung et al. (2008) demonstrated that the activation of PKCδ
in HCC cells through proteolytic cleavage elicited apoptotic
cell death rather than survival. Similarly, the activation of
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FIGURE 5 | Knockdown of p53 in HepG2 cells increases the resistance to both sorafenib and OSU-2S. (A) Western blot analysis of the differential
expression levels of p53 in untransfected HepG2 cells versus HepG2 cells transfected by scrambled shRNA or shRNA against p53. Effect of p53 knockdown on the
sensitivity of HepG2 cells to (B) sorafenib or (C) OSU-2S-mediated inhibition of cell viability measured by MTT assay. Points, mean; bars, SD (n = 6).
FIGURE 6 | The over-expression of p53 in Hep3B cells restores the sensitivity to both sorafenib and OSU-2S. (A) Western blot analysis of the differential
expression levels of p53 in untransfected Hep3B cells versus Hep3B cells over-expressing p53. Effect of p53 over-expression on the sensitivity of Hep3B cells to (B)
sorafenib or (C) OSU-2S-mediated inhibition of cell viability measured by MTT assay. Points, mean; bars, SD (n = 6). (D) Fluorescence and direct light microscopy of
Hep3B cells over-expressing p53 on the indicated treatments.
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PKCδ through proteolytic cleavage followed by nuclear
translocation or allosteric activation caused significant inhibition
of proliferation and apoptosis different cancer cells (Fujii et al.,
2000; DeVries et al., 2002). On the other hand, PKCδ inhibition
was reported as a key player for sensitizing TRAIL-resistant
human fibrosarcoma (Hayashi et al., 2014). Other studies
indicated that activation of PKC with phorbol-12-myristate-13-
acetate (PMA), blocks TRAIL, and TNF-α induced apoptosis
(Sarker et al., 2001; Harper et al., 2003). The discrepancies in
the consequence of PKCδ activation whether enhancement or
suppression of apoptosis appears to depend on the initiating
signal and the type of cancer cells (Garg et al., 2014).
It is worth noting that PKCδ has also been shown to
suppress cell migration, and its absence could contribute to
both cell survival and metastasis in human cancers (Jackson
et al., 2005). In the current study, the activation of PKCδ by
OSU-2S caused a significant inhibition in HCC cell invasion
and migration. In similar reports, the overexpression of PKCδ
inhibited breast cancer cell migration (Jackson et al., 2005). On
the contrary, PKCδ activity was required in integrin-mediated
metastatic melanoma invasion and EGFR-induced migration in
fibroblasts (Iwabu et al., 2004; Putnam et al., 2009). Also, HIF-2α
promoted PKCδ-mediated migration in HCC through enhanced
phosphorylation (Cao et al., 2016). Since there is a considerable
heterogeneity within tumor cells and due to the involvement of
several signaling pathways in the process of migration/invasion,
the events following PKCδ activation could vary depending on
the cell type and the used stimulus (Basu and Pal, 2010).
In vitro studies showed that PKCδ enhances cancer cell
apoptosis by antagonizing ERK phosphorylation (Li et al.,
2012). The potentiated effect of the combination on ERK
phosphorylation can be explained based on the reported ability
of PKCδ to inhibit ERK phosphorylation, which is similar to
the major anticancer mechanism of sorafenib (Li et al., 2012).
Similarly, PKCδ inhibited hepatocyte growth factor (HGF)-
induced phosphorylation of ERK (Hu et al., 2013). In addition,
PKCδ activity was required to activate the pro-apoptotic ERK
signaling during B cell development (Limnander et al., 2011).
Conversely, PKCδ activation through phosphorylation induced
a sustained activation of ERK in response to etoposide-induced
apoptosis in glioma cells (Lomonaco et al., 2008). The difference
in response to PKCδ activation among MAPK family members
could be explained based on the way of PKCδ activation being
through proteolytic cleavage or allosteric and the nature of
cells.
In this study, we demonstrated that p53 status in HCC
cells predicts their sensitivity toward both sorafenib and OSU-
2S. The tumor-suppressor protein p53 is a master regulator of
apoptosis, in response to cellular stress (Farnebo et al., 2010).
Since the tumor-suppressing effects of PKCδ are mediated at
least in part through activating p53 transcription (Abbas et al.,
2004), the existence of wild type p53 in HepG2 cells could
partially explain their relatively higher sensitivity to both drugs
than the other HCC cell lines which lack functional p53. The
role of p53 in the differential sensitivity to both sorafenib
and OSU-2S was confirmed by abrogating the sensitivity of
HepG2 cell by p53 knockdown and rendering Hep3B cells
much more sensitive by p53 overexpression. This observation
can be also supported by the ability of sorafenib to up-
regulate p53 expression and to induce p53 family-dependent
apoptosis in HCC cells (Fernando et al., 2012; Wei et al.,
2015).
CONCLUSION
OSU-2S could effectively augment the anti-proliferative effect
of sorafenib in HCC cell lines, in part, through the activation
of PKCδ. The p53 status in HCC cells predicts their sensitivity
toward both sorafenib and OSU-2S. The current study
underscores evidence about the translational potential of OSU-
2S/sorafenib combination and encourages future in vivo safety
studies to allow the extrapolation into the clinical setting as a
therapeutically relevant approach for HCC patients.
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